SGMO Stock Summary and Trading Ideas (Sangamo Therapeutics | NASDAQ:SGMO)

Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Sangamo Therapeutics trades on the NASDAQ stock market under the symbol SGMO.

As of April 1, 2026, SGMO stock price climbed to $0.26 with 7,767,938 million shares trading.

SGMO has a beta of 1.22, meaning it tends to be more sensitive to market movements. SGMO has a correlation of 0.05 to the broad based SPY ETF.

SGMO has a market cap of $96.68 million. This is considered a Micro Cap stock.

Last quarter Sangamo Therapeutics reported $14 million in Revenue and -$.11 earnings per share. This fell short of revenue expectation by $-24 million and missed earnings estimates by -$.09.

In the last 3 years, SGMO traded as high as $3.18 and as low as $.21.

The top ETF exchange traded funds that SGMO belongs to (by Net Assets): VTI, VXF, SCHA, PRFZ, ITOT.

SGMO has underperformed the market in the last year with a price return of -60.3% while the SPY ETF gained +18.5%. SGMO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -38.1% and -31.6%, respectively, while the SPY returned -3.6% and -2.1%, respectively.

SGMO support price is $.23 and resistance is $.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SGMO shares will trade within this expected range on the day.